Rarecells Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$13M
- Investors
-
3
Rarecells General Information
Description
Developer of a biotechnology platform designed to facilitate early-stage detection of cancer using circulating tumor cells. The company's platform conducts circulating tumor cell tests on a given blood sample, analyzes gradual cell growth, tracks serum secretion markers, abnormal and rapid multiplication of biomolecules and protein cells, and sends signals when a high number of circulating non-tumor epithelial cells is released into the blood, enabling medical institutions to offer alternative cancer treatment therapies that are non-invasive, painless, and cheap.
Contact Information
Website
www.rarecells.comCorporate Office
- Alexandria LaunchLabs-Columbia, 3960 Broadway
- 6th Floor
- New York, NY 10032
- United States
Corporate Office
- Alexandria LaunchLabs-Columbia, 3960 Broadway
- 6th Floor
- New York, NY 10032
- United States
Rarecells Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 09-Dec-2021 | $13M | Completed | Generating Revenue |
Rarecells Patents
Rarecells Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024398398-A1 | Screening samples for subclinical indicia of cancer | Pending | 14-Dec-2023 | ||
| EP-4824278-A1 | Screening samples for subclinical indicia of cancer | Pending | 14-Dec-2023 | ||
| WO-2025129182-A1 | Screening samples for subclinical indicia of cancer | Inactive | 14-Dec-2023 | ||
| WO-2024259369-A1 | Compositions targeting giant cells in blood disorders | Inactive | 14-Jun-2023 | ||
| US-20260227409-A1 | Distinctive identification and use of a liquid biopsy cancer biomarker for cancer detection, management and treatment | Pending | 17-Jan-2023 | G01N33/5759 |
Rarecells Signals
Rarecells Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Globivest | Venture Capital | Minority | ||
| Manta Capital Advisors | Venture Capital | Minority | ||
| YADAY | Family Office | Minority |
Rarecells FAQs
-
When was Rarecells founded?
Rarecells was founded in 2009.
-
Where is Rarecells headquartered?
Rarecells is headquartered in New York, NY.
-
What is the size of Rarecells?
Rarecells has 31 total employees.
-
What industry is Rarecells in?
Rarecells’s primary industry is Diagnostic Equipment.
-
Is Rarecells a private or public company?
Rarecells is a Private company.
-
What is Rarecells’s current revenue?
The current revenue for Rarecells is .
-
How much funding has Rarecells raised over time?
Rarecells has raised $13M.
-
Who are Rarecells’s investors?
Globivest, Manta Capital Advisors, and YADAY have invested in Rarecells.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process